On 2 3 miles orney Docket No.: 4759.224-US

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Serial No.: 09/940,963 /

Group Art Unit: To be assigned

Filed: August 28, 2001

Examiner: To be assigned

For: Heterocyclic Compounds, their Preparation and Use

## RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Commissioner for Patents Washington, DC 20231

Sir:

In response to the Notice to File Corrected Application Papers dated September 18, 2001 (a copy thereof is attached hereto), Applicants submit a Preliminary Amendment incorporating the requested abstract for the above-captioned application.

Additionally, the Cross Reference to Related Application section has been added to the specification.

Please charge any debits or overpayments to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

Date: November 16, 2001

Respectfully submitted


Peter J. Waibel, Reg. No. 43,228 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123

(212) 007 0123

23650

PATENT TRADEMARK OFFICE



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 2023I

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

www.uspto.gov

09/940,963

08/28/2001

Lone Jeppesen

ATTORNEY DOCKET NUMBER
4759 224-US

**CONFIRMATION NO. 7017** 

FORMALITIES LETTER
\*OC000000006567653\*

Reza Green, Esq. Novo Nordisk of North America, Inc. Suite 6400 405 Lexington Avenue New York, NY 10174-6401

Date Mailed: 09/18/2001

## NOTICE TO FILE CORRECTED APPLICATION PAPERS

## Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

 An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE